ProCE Banner Activity

My Thoughts on Necitumumab for Patients With Newly Diagnosed Squamous NSCLC

Clinical Thought
Are you considering necitumumab for your patients with squamous NSCLC? David R. Gandara, MD, shares his thoughts on using this agent.

Released: March 02, 2016

Expiration: March 01, 2017

No longer available for credit.

Share

Faculty

David R. Gandara

David R. Gandara, MD

Professor of Clinical Medicine
Associate Director for Clinical Research
University of California Davis Cancer Center
Davis, California

Provided by

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Boehringer Ingelheim

Genentech BioOncology

Lilly

Novartis Oncology

Faculty Disclosure

Primary Author

David R. Gandara, MD

Professor of Clinical Medicine
Associate Director for Clinical Research
University of California Davis Cancer Center
Davis, California

David R. Gandara, MD, has disclosed that he has received consulting fees from AstraZeneca, Boehringer Ingelheim, Celgene, Clovis, Genentech, Guardant Health, Lilly, Merck, Novartis, Pfizer, Response Genetics, and Synta and research support from AstraZeneca/Medi, Bristol-Myers Squibb, Clovis, Genentech, Johnson & Johnson, Lilly, Merck, and Novartis.